Our observation of FA/BRCA deficient cancer cells having higher PD-L1 expression has also been reported in BRCA-deficient ovarian and breast cancer and considered a biomarker of response to anti-PD1 therapy [25, 26]. This evidence concerns the gene CD274 and breast carcinoma.